Compare RXRX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | PHVS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2021 | 2020 |
| Metric | RXRX | PHVS |
|---|---|---|
| Price | $2.48 | $31.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $6.77 | ★ $58.19 |
| AVG Volume (30 Days) | ★ 21.1M | 467.0K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.50 | $23.15 |
| 52 Week High | $5.24 | $43.25 |
| Indicator | RXRX | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 40.50 |
| Support Level | N/A | $28.16 |
| Resistance Level | $3.66 | $31.49 |
| Average True Range (ATR) | 0.29 | 1.65 |
| MACD | -0.12 | -0.29 |
| Stochastic Oscillator | 0.31 | 15.28 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.